Recent clinical trials have further shown that reducing high Lp(a) levels can decrease the risks of cardiovascular event (23, 24), suggesting that targeting Lp(a) could enhance current CHD secondary prevention strategies. This evidence concerns the gene LPA and coronary artery disorder.